Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Strom

Showing results (401-410 of 659) with videos related to

Pageof 66
Sort By:
Transplantation|June 30, 1998
Increased CD40 ligand gene expression during human renal and murine islet allograft rejectionX X Zheng, A D Schachter, L Vasconcellos, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 24, 1999
Induction of allograft tolerance in the absence of Fas-mediated apoptosisX C Li, Y Li, I Dodge, et al.
Heart (British Cardiac Society)|December 21, 2019
Association between procedure appropriateness and patient-reported outcomes after percutaneous coronary interventionJesse Xiaolong Yang, Margaret J Stevenson, Linda Valsdottir, et al.
Nature|May 2, 2006
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsEstelle Bettelli, Yijun Carrier, Wenda Gao, et al.
Transplantation Proceedings|February 1, 1995
Cytokine and alloantibody networks in long-term cardiac allografts in rapamycin-treated sensitized rat recipientsB Wasowska, K J Wieder, W W Hancock, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 1, 1984
Cyclosporine therapy of rat heart allograft recipients and release of interleukins (IL 1, IL 2, IL 3): a role for IL 3 in graft tolerance?M Abbud-Filho, J W Kupiec-Weglinski, J L Araujo, et al.
JAMA Cardiology|September 26, 2019
Association of Frailty With 30-Day Outcomes for Acute Myocardial Infarction, Heart Failure, and Pneumonia Among Elderly AdultsHarun Kundi, Rishi K Wadhera, Jordan B Strom, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1989
Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activationG Walz, B Zanker, K Brand, et al.
Protein Engineering|December 1, 1987
Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion proteinD P Williams, K Parker, P Bacha, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1985
The events of primary T cell activation can be staged by use of Sepharose-bound anti-T3 (64.1) monoclonal antibody and purified interleukin 1J M Williams, D Deloria, J A Hansen, et al.
Pageof 66

Showing results (401-410 of 659) with videos related to

Sort By:
Pageof 66
Transplantation|June 30, 1998
Increased CD40 ligand gene expression during human renal and murine islet allograft rejectionX X Zheng, A D Schachter, L Vasconcellos, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 24, 1999
Induction of allograft tolerance in the absence of Fas-mediated apoptosisX C Li, Y Li, I Dodge, et al.
Heart (British Cardiac Society)|December 21, 2019
Association between procedure appropriateness and patient-reported outcomes after percutaneous coronary interventionJesse Xiaolong Yang, Margaret J Stevenson, Linda Valsdottir, et al.
Nature|May 2, 2006
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsEstelle Bettelli, Yijun Carrier, Wenda Gao, et al.
Transplantation Proceedings|February 1, 1995
Cytokine and alloantibody networks in long-term cardiac allografts in rapamycin-treated sensitized rat recipientsB Wasowska, K J Wieder, W W Hancock, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 1, 1984
Cyclosporine therapy of rat heart allograft recipients and release of interleukins (IL 1, IL 2, IL 3): a role for IL 3 in graft tolerance?M Abbud-Filho, J W Kupiec-Weglinski, J L Araujo, et al.
JAMA Cardiology|September 26, 2019
Association of Frailty With 30-Day Outcomes for Acute Myocardial Infarction, Heart Failure, and Pneumonia Among Elderly AdultsHarun Kundi, Rishi K Wadhera, Jordan B Strom, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1989
Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activationG Walz, B Zanker, K Brand, et al.
Protein Engineering|December 1, 1987
Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion proteinD P Williams, K Parker, P Bacha, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1985
The events of primary T cell activation can be staged by use of Sepharose-bound anti-T3 (64.1) monoclonal antibody and purified interleukin 1J M Williams, D Deloria, J A Hansen, et al.
Pageof 66